Pancreatic cancer survival rates have more than doubled in the past decade. It’s not because of a single breakthrough, but better knowledge of the cancer, and more creative use of existing tools. The advances are benefitting all ages.
This multicenter cohort study develops and assesses the validity of a deep learning model for predicting immune checkpoint inhibitor response in patients with advanced non−small…
FDA Approval Alert brings together the most up-to-date information on the latest FDA approvals in oncology. On this page, read, watch, and listen to the…
Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.
Chairs : Hermann Einsele, Maria Theresa Krauth, Maria Victoria Mateos, Omar Nadeem April 3-5, 2025 – Vienna, Austria Chairs: Hermann Einsele, Maria Theresa Krauth, Maria-Victoria…
Immunostaining for annexin A10 (ANXA10) and p53 was mainly negative in benign urothelium, ANXA10 expression was detected in low-grade urothelial carcinoma, and p53 expression was…
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in…
A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s…
Two year grant of $130,000 for a postdoctoral or clinical research fellow to conduct research projects focused on hematologic malignancies.
Karen Lu, MD, is a nationally recognized physician-scientist who focuses her clinical and research interests on the surgical and medical treatment of women with ovarian…
European Medicines Agency recommends repotrectinib for ROS1-positive NSCLC; FDA approves therapies for NSCLC, LS-SCLC as well as a new diagnostic tool for identifying MET exon…
